ESMO Asia 2024 | Professor Xuefeng Qiu Reviews Progress in Prostate Cancer Diagnosis and Treatment, Shares Research Achievements from Gulou Hospital

ESMO Asia 2024 | Professor Xuefeng Qiu Reviews Progress in Prostate Cancer Diagnosis and Treatment, Shares Research Achievements from Gulou Hospital

As 2024 draws to a close, the field of oncology celebrates the year’s grand finale with the ESMO ASIA Annual Meeting. The conference not only attracted top scholars and researchers from across Asia and the global oncology community but also showcased numerous breakthroughs in urologic oncology. On-site at the conference, Urology Frontier invited Professor Xuefeng Qiu from Nanjing Drum Tower Hospital，The Affiliated Hospital of Nanjing University Medical School to summarize this year’s advancements in the field of prostate cancer, share his team’s research selected for ESMO ASIA, and discuss future trends in the field.
ILCA 2024 | Professor Masatoshi Kudo Shares Insights on the Prognostic and Treatment-Guiding Value of ORR, DpR, and DoR in HCC Patients

ILCA 2024 | Professor Masatoshi Kudo Shares Insights on the Prognostic and Treatment-Guiding Value of ORR, DpR, and DoR in HCC Patients

Previous studies have demonstrated that short-term efficacy metrics, such as objective response rate (ORR), are associated with long-term survival outcomes, such as overall survival (OS), in targeted therapy for advanced hepatocellular carcinoma (HCC). At the 2024 International Liver Cancer Association (ILCA) Conference, Professor Masatoshi Kudo from Kinki University Faculty of Medicine in Japan presented exploratory analyses on the correlation between efficacy metrics like depth of response (DpR) and duration of response (DoR) with OS benefits. He also discussed their value in guiding systemic drug therapy combined with local treatments. We interviewed Professor Kudo to share his key findings.
ESMO Asia 2024 | Breakthrough Results from Qilu Pharmaceuticals’ Iparomlimab and Tuvonralimab (QL1706)

ESMO Asia 2024 | Breakthrough Results from Qilu Pharmaceuticals’ Iparomlimab and Tuvonralimab (QL1706)

The European Society for Medical Oncology Asia (ESMO Asia) Congress was held in Singapore，from 6 to 8 December 2024. ESMO Asia is an annual congress specifically focused on multidisciplinary oncology in the Asian region, providing a remarkable platform for participants to share and discuss the latest research findings, clinical trials, and treatment strategies in the field. During the three-day event, Qilu Pharmaceutical unveiled the latest findings from three key studies on iparomlimab and tuvonralimab (QL1706), a bifunctional MabPair® product of anti-PD-1 IgG4 and anti-CTLA-4 IgG1 antibodies.
Advancing Treatment Strategies for Muscle-Invasive Bladder Cancer: Insights from Dr. Brigida Maiorano at ESMO Asia 2024

Advancing Treatment Strategies for Muscle-Invasive Bladder Cancer: Insights from Dr. Brigida Maiorano at ESMO Asia 2024

Muscle-invasive bladder cancer (MIBC) presents unique challenges due to its aggressive nature and the complexity of its treatment. At ESMO Asia 2024, Dr. Brigida Maiorano shared valuable insights into evolving strategies, including bladder-preserving approaches, novel clinical trial designs, and the latest advances in targeted therapies. In this exclusive interview with Oncology Frontier, Dr. Maiorano discusses current standards, promising clinical results, and her vision for improving outcomes in MIBC.
Dr. Hao Zeng: Advancing Uro-Oncology with Cutting-Edge Technologies and Promoting Standardized Care in Grassroots Settings

Dr. Hao Zeng: Advancing Uro-Oncology with Cutting-Edge Technologies and Promoting Standardized Care in Grassroots Settings

Focusing on global progress while highlighting Chinese innovations, the 8th West China Uro-Oncology Tianfu Academic Conference and the 10th Uro-Oncology Annual Meeting of the Sichuan Anti-Cancer Association were successfully held in Chengdu, Sichuan. Organized by the Sichuan Anti-Cancer Association and hosted by its Urological and Male Reproductive Tumors Committee in collaboration with the Department of Urology at West China Hospital, Sichuan University, the conference brought together experts to discuss the latest advancements. Following the event, Urology Frontier had the privilege of interviewing the conference’s executive chair, Dr. Hao Zeng, to explore the highlights of the meeting and the key areas for enhancing diagnostic and treatment capabilities for grassroots physicians in uro-oncolog
CCHIO 2024 | Dr. Gang Ding: The Era of “Integration” — Exploring Tumor Rehabilitation and Health Education for a China-Specific Oncology Prevention

CCHIO 2024 | Dr. Gang Ding: The Era of “Integration” — Exploring Tumor Rehabilitation and Health Education for a China-Specific Oncology Prevention

The 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO) concluded successfully on November 17. Following the strategic framework of "collaborative integration" in disciplinary development, the conference established dedicated sessions on tumor rehabilitation, health education, cancer prevention, and screening. These sessions offered comprehensive and multidimensional insights into new perspectives, technologies, and concepts for the full-cycle management of oncology, spanning prevention, screening, diagnosis, treatment, and rehabilitation.

Dr. Zhaochong Zeng: Advancing Liver Cancer Care with Targeted Radiotherapy Strategies and Dual MDT Approaches

China bears a significant burden of liver cancer. To prevent its onset and progression, the country, society, and countless physicians have undertaken extensive measures under the framework of "three-level prevention," achieving remarkable progress. With the increasing proportion of early diagnosis and treatment of liver cancer in recent years, a key focus for radiotherapy specialists has been how to precisely select appropriate radiotherapy methods for early-stage liver cancer patients to improve their prognosis. Oncology Frontier interviewed Dr. Zhaochong Zeng from Zhongshan Hospital, Fudan University, to discuss liver cancer prevention and control in China, explore strategies and advantages of proton therapy, brachytherapy, and combined radiotherapy with interventional treatments for early-stage liver cancer, and outline the role of the radiotherapy department in multidisciplinary team (MDT) development for liver cancer.
CCHIO 2024 | Dr. Hong Liu: New Perspectives on Breast Cancer Rehabilitation – The Importance of Psychological Well-being and Multidisciplinary

CCHIO 2024 | Dr. Hong Liu: New Perspectives on Breast Cancer Rehabilitation – The Importance of Psychological Well-being and Multidisciplinary

Breast cancer not only threatens patients' lives but also imposes a heavy psychological burden on women. As the number of breast cancer cases continues to rise, its rehabilitation is gaining increasing attention from society. How to effectively promote comprehensive recovery for breast cancer patients has become an important issue in the medical field. During the 2024 Chinese Congress on Holistic Integrative Oncology (CCHIO), Oncology Frontier interviewed Dr. Hong Liu, Chair of the Breast Cancer Integrated Rehabilitation Committee of the Chinese Anti-Cancer Association and a leading expert at Tianjin Medical University Cancer Institute and Hospital. Professor Liu discussed the importance of psychological rehabilitation for breast cancer patients, prospects for the development of the rehabilitation field, applications of new technologies and methods, and the significance of multidisciplinary collaboration. Drawing on her extensive clinical experience, Professor Liu shed light on new trends in breast cancer rehabilitation, offering hope for patients.
The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024

The 66th American Society of Hematology (ASH) Annual Meeting was grandly held in San Diego, USA, from December 7th to 10th, 2024. As one of the most influential platforms for scientific communication in hematology, this global event attracted over 25,000 professionals, including clinicians, researchers, and healthcare leaders from more than 100 countries. The conference covered all aspects of malignant and non-malignant hematology, from cutting-edge research to clinical practice and therapeutic innovation, reflecting the latest advancements and future trends in the field.